Published in Mol Psychiatry on June 10, 2014
Loss of pattern separation performance in schizophrenia suggests dentate gyrus dysfunction. Schizophr Res (2014) 0.91
Translating the MAM model of psychosis to humans. Trends Neurosci (2014) 0.89
Anterior cingulate cortex-related connectivity in first-episode schizophrenia: a spectral dynamic causal modeling study with functional magnetic resonance imaging. Front Hum Neurosci (2015) 0.82
Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry (2015) 0.82
Alterations in hippocampal connectivity across the psychosis dimension. Psychiatry Res (2015) 0.81
The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. Adv Pharmacol (2016) 0.79
GABA System in Schizophrenia and Mood Disorders: A Mini Review on Third-Generation Imaging Studies. Front Psychiatry (2016) 0.79
Contribution of substantia nigra glutamate to prediction error signals in schizophrenia: a combined magnetic resonance spectroscopy/functional imaging study. NPJ Schizophr (2015) 0.77
Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders. Biol Psychiatry (2017) 0.75
Transmembrane protein 108 is required for glutamatergic transmission in dentate gyrus. Proc Natl Acad Sci U S A (2017) 0.75
Developmental expression of mGlu2 and mGlu3 in the mouse brain. Gene Expr Patterns (2016) 0.75
Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment. Transl Psychiatry (2016) 0.75
Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis. Transl Psychiatry (2017) 0.75
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci (2005) 11.68
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science (2007) 6.48
Simultaneous in vivo spectral editing and water suppression. NMR Biomed (1998) 5.09
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry (2011) 4.91
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 3.34
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med (2012) 3.30
Human postmortem tissue: what quality markers matter? Brain Res (2006) 2.92
The hippocampal formation in schizophrenia. Am J Psychiatry (2010) 2.82
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol (2006) 2.73
Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med (1994) 2.39
Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry (2013) 2.37
NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci (1996) 2.35
Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry (2004) 2.27
Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry (1992) 2.21
Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology (2001) 2.18
Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry (2007) 2.12
Hippocampal deformities in schizophrenia characterized by high dimensional brain mapping. Am J Psychiatry (2002) 2.11
Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry (2005) 2.08
Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2012) 1.91
A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res (2002) 1.87
Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep (2010) 1.87
In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol (2002) 1.79
Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull (2011) 1.78
Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry (2000) 1.75
Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry (2002) 1.59
Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci (2011) 1.57
Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res (1990) 1.54
Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res (2011) 1.51
Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry (2009) 1.49
Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res (2009) 1.34
Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport (2001) 1.31
In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull (2012) 1.28
Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry (2008) 1.27
Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry (2008) 1.13
Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry (2011) 1.09
Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology (2012) 1.02
Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage (2010) 1.01
A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry (1999) 0.98
Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. Med Sci Monit (2009) 0.95
Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophr Res (2012) 0.89
Brain gamma-aminobutyric acid measurement by proton double-quantum filtering with selective J rewinding. Magn Reson Med (2005) 0.88
Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol Psychiatry (2010) 0.87
Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLoS One (2011) 0.85
Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophr Res (2009) 0.83
Altered 13C glucose metabolism in the cortico-striato-thalamo-cortical loop in the MK-801 rat model of schizophrenia. J Cereb Blood Flow Metab (2010) 0.81